Clinipace expands global CRO ops with Paragon takeover

The ongoing consolidation of the CRO industry continued today as Clinipace Worldwide announced it will absorb Paragon Biomedical's operations. Morrisville, NC-based Clinipace says it will now double in size to more than 430 staffers worldwide. "With complementary strengths, we're thrilled to be combining forces with Clinipace Worldwide to create one globally integrated company," commented Gena Reed, founder and CEO of Paragon Biomedical. "Moreover, the company cultures and senior leadership teams blend well, creating a corporate marriage that is ideal for our employees and customers." Release

Suggested Articles

Monoclonal antibodies developer Xencor extended a strategic alliance formed in 2016 with Selexis with four commercial license agreements.

Raxone is currently in a phase 3 study on DMD patients who are taking glucocorticoids.

The SuperHuman library contains over 5,000 hits against each of the 26 Distributed Bio targets in immunology and neurodegeneration.